drugset / Trial / NCT00253123

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia

NCT00253123

Phase 3 Completed 626 enrolled Janssen, LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral disturbances associated with dementia.

Timeline

Start
Primary completion
Completion
1997-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 0.5 mg Oral
Subject Risperidone Other / unclassified 1 mg Oral
Subject Risperidone Other / unclassified 2 mg Oral